Key result
Inhibiting TF-PAR2 signaling suppresses gluconeogenic, lipogenic, and inflammatory pathways in diet-induced obese mice.
Why the study?
Obesity-associated hepatic inflammation is mechanistically linked to steatosis and hepatic insulin resistance, but the role of coagulation signaling via tissue factor and PAR2 in these processes is unclear.
Inhibition of hematopoietic TF-PAR2 signaling reduces hepatic inflammation, steatosis, and gluconeogenesis in obese mice, highlighting a potential mechanistic pathway contributing to obesity-induced type 2 diabetes.
Answers are grounded in this paper and cite their sources.
TF/PAR2 signaling may link obesity to hepatic insulin resistance; leaves open whether pathway inhibition improves glycemia in T2D.
Failure to inhibit hepatic gluconeogenesis is a major mechanism contributing to fasting hyperglycemia in type 2 diabetes and, along with steatosis, is the hallmark of hepatic insulin resistance. Obesity is associated with chronic inflammation in multiple tissues, and hepatic inflammation is mechanistically linked to both steatosis and hepatic insulin resistance. Here, we delineate a role for coagulation signaling via tissue factor (TF) and proteinase-activated receptor 2 (PAR2) in obesity-mediated hepatic inflammation, steatosis, and gluconeogenesis. In diet-induced obese mice, TF tail signaling independent of PAR2 drives CD11b(+)CD11c(+) hepatic macrophage recruitment, and TF-PAR2 signaling contributes to the accumulation of hepatic CD8(+) T cells. Transcripts of key pathways of gluconeogenesis, lipogenesis, and inflammatory cytokines were reduced in high-fat diet-fed mice that lack the cytoplasmic domain of TF (F3) (TF(ΔCT)) or that are deficient in PAR2 (F2rl1), as well as by pharmacological inhibition of TF-PAR2 signaling in diet-induced obese mice. These gluconeogenic, lipogenic, and inflammatory pathway transcripts were similarly reduced in response to genetic ablation or pharmacological inhibition of TF-PAR2 signaling in hematopoietic cells and were mechanistically associated with activation of AMP-activated protein kinase (AMPK). These findings indicate that hematopoietic TF-PAR2 signaling plays a pivotal role in the hepatic inflammatory responses, steatosis, and hepatic insulin resistance that lead to systemic insulin resistance and type 2 diabetes in obesity.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2014) studied Obesity, hepatic inflammation, steatosis, and insulin resistance. Genetic ablation or pharmacological inhibition of TF-PAR2 signaling vs. Control diet-induced obese mice was evaluated on Hepatic inflammation, steatosis, and gluconeogenesis pathway transcripts. Genetic ablation or pharmacological inhibition of TF-PAR2 signaling reduced gluconeogenic, lipogenic, and inflammatory pathway transcripts in diet-induced obese mice.
Synapse has enriched 10 related papers. Consider them for comparative context: